



## Klinik für Urologie: Erfasste Publikationen aus 2023

ID: 514741

Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer.

**BJUI Compass** 2023; 4(1): 123-129; Impact Factor=1.6; Impact Factor 2024=1.9; Typ=Journal Article; Bravi CA, Heidenreich A, Fossati N, Gandaglia G, Suardi N, Mazzone E, Stabile A, Cucchiara V, Osmonov D, Juenemann KP, Karnes RJ, Kretschmer A, Buchner A, Stief C, Hiester A, **Albers P**, Devos G, Joniau S, Van Poppel H, Grubmüller B, Shariat S, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A, Pfister D

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 542912

Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit.

**BMJ** 2023; 381(): ; Impact Factor=93.6; Impact Factor 2024=43.0; Typ=Journal Article; Vickers A, O'Brien F, Montorsi F, Galvin D, Bratt O, Carlsson S, Catto JW, Krilaviciute A, Philbin M, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 540399

Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets.

**Br J Cancer** 2023; 129(10): 1580-1589; Impact Factor=6.4; Impact Factor 2024=6.8; Typ=Journal Article; Bremmer F, **Pongratanakul P**, **Skowron M**, **Che Y**, Richter A, Küffer S, Reuter-Jessen K, Bohnenberger H, Pauls S, Kresbach C, Schüller U, Stühler K, Ströbel P, **Albers P**, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 535931

Genome-scale CRISPR screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumours.

**Br J Cancer** 2023; 128(12): 2270-2282; Impact Factor=6.4; Impact Factor 2024=6.8; Typ=Journal Article;

Funke K, Einsfelder U, Hansen A, Arévalo L, Schneider S, **Nettersheim D**, Stein V, Schorle H

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 534942

Influence of benign prostatic hyperplasia patterns detected with MRI on the clinical outcome after prostatic artery embolization

**CVIR Endovasc** 2023; 6(1): ; Impact Factor=1.2; Impact Factor 2024=1.5; Typ=Boschheidgen M, **Al-Monajjed R**, Minko P, Jannusch K, Ullrich T, Radke KL, **Michalski R**, **Radtke JP**, **Albers P**, Antoch G, Schimmoeller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 539543

Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment.

**Cancer Med** 2023; 12(16): 16829-16836; Impact Factor=2.9; Impact Factor 2024=3.1; Typ=Journal Article;

Majewski M, Paffenholz P, Ruf C, **Che Y**, Seidel C, Heinzlbecker J, Schmelz HU, Matthies C, **Albers P**, Bokemeyer C, Heidenreich A, Pichler M, Nestler T, GTCSSG (German Testicular Cancer Study Group) Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 507647

Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer.

**Cancer Med** 2023; 12(5): 5222-5232; Impact Factor=2.9; Impact Factor 2024=3.1; Typ=Journal Article;

Olah C, Reis H, **Hoffmann MJ**, Mairinger F, Ting S, Hadaschik B, Krafft U, Grünwald V, Nyirady P, Varadi M, Györfy B, Kiss A, Szekely E, Sjö Dahl G, Szarvas T Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 536799

Intra-Individual Comparison of Physiologic [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis.

**Cancers (Basel)** 2023; 15(10): ; Impact Factor=4.5; Impact Factor 2024=4.4; Typ=Journal Article;

Novruzov E, Schmitt D, Mattes-György K, Beu M, Mori Y, Dabir M, **Radtke JP**, **Niegisch G**, **Albers P**, Schimmöller L, Antoch G, Antke C, Giesel FL, Mamlins E Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 536567

Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.

**Clin Cancer Res** 2023; 29(10): 1887-1893; Impact Factor=10.0; Impact Factor 2024=10.2;

Typ=Randomized Controlled Trial;Multicenter Study;Clinical Trial, Phase II;Journal Article;Research Support, Non-U.S. Gov't;

Omlin A, Cathomas R, von Amsberg G, Reuter C, Feyerabend S, Loidl W, Boegemann M, **Lorch A**, Heidenreich A, Tsaui I, Larcher-Senn J, Buck SAJ, Mathijssen RHJ, Jaehde U, Gillessen S, Joerger M Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 540641

Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.

**Eur J Cancer** 2023; 192(): ; Impact Factor=7.6; Impact Factor 2024=7.1; Typ=Randomized Controlled Trial;Clinical Trial, Phase III;Journal Article;Research Support, Non-U.S. Gov't;

Fizazi K, Shore ND, Smith M, Ramos R, Jones R, **Niegisch G**, Vjaters E, Wang Y, Srinivasan S, Sarapohja T, Verhulst F Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 543507

Multiparametric MRI characteristics of prostatitis and atrophy in the peripheral zone in men without prostate cancer.

**Eur J Radiol** 2023; 169(): ; Impact Factor=3.2; Impact Factor 2024=3.3; Typ=Journal Article;

**Al-Monajjed R**, **Radtke JP**, **Thomas M**, Boschheidgen M, Drewes LR, Ullrich T, Rau T, Esposito I, Antoch G, **Albers P**, Lopez-Cotarelo C, Schimmöller L Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 545291

Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal

Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass).

**Eur Urol** 2023; 84(6): 571-578; Impact Factor=25.3; Impact Factor 2024=25.2; Typ=Journal Article; Grünwald V, Ivanyi P, Zschäbitz S, Wirth M, Staib P, Schostak M, Dargatz P, Müller L, Metz M, Bergmann L, Steiner T, Welslau M, **Lorch A**, Rafiyan R, Hellmis E, Darr C, Schütt P, Meiler J, Kretz T, Loidl W, Flörcken A, Mänz M, Hinke A, Hartmann A, Grüllich C  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 538587

Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST).

**Eur Urol** 2023; 84(1): 25-31; Impact Factor=25.3; Impact Factor 2024=25.2; Typ=Clinical Trial, Phase II;Journal Article;

**Hiester A**, **Che Y**, **Lusch A**, Kuß O, **Niegisch G**, **Lorch A**, **Arsov C**, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 536517

Re: Association of Prostate-specific Antigen Screening Rates with Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities: Prostate cancer screening needs not only to be well meant but also well done.

**Eur Urol** 2023; 83(4): 369-370; Impact Factor=25.3; Impact Factor 2024=25.2; Typ=Journal Article;Comment;

**Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 536815

Reply to Kirti Singh, Swarnendu Mandal, Manoj Kumar Das, Prasant Nayak, and Sambit Tripathy's Letter to the Editor re: Andreas Hiester, Yue Che, Achim Lusch, et al. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). *Eur Urol*. In press. <https://doi.org/10.1016/j.eururo.2022.10.021>.

**Eur Urol** 2023; 83(6): ; Impact Factor=25.3; Impact Factor 2024=25.2; Typ=Clinical Trial, Phase II;Letter;Comment;

**Che Y**, **Hiester A**, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 536498

Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized Trial.

**Eur Urol Oncol** 2023; 6(1): 49-55; Impact Factor=8.3; Impact Factor 2024=9.3; Typ=Randomized Controlled Trial;Journal Article;

Saner YM, Wiesenfarth M, Weru V, Ladyzhensky B, Tschirdewahn S, Püllen L, Bonekamp D, Reis H, Krafft U, Heß J, Kesch C, Darr C, Forsting M, Wetter A, Umutlu L, Haubold J, Hadaschik B, **Radtke JP**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 540556

Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer.

**Eur Urol Oncol** 2023; 6(6): 566-573; Impact Factor=8.3; Impact Factor 2024=9.3; Typ=Journal Article;

Krilaviciute A, Becker N, **Lakes J**, **Radtke JP**, Kuczyk M, Peters I, Harke NN, Debus J, Koerber SA, Herkommer K, Gschwend JE, Meissner VH, Benner A, Seibold P, Kristiansen G, Hadaschik B, **Arsov C**, Schimmöller L, Giesel FL, Antoch G, Makowski M, Wacker F, Schlemmer HP, Kaaks R, **Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 539946

Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort.

**Eur. Urol. Open Sci.** 2023; 53(): 31-37; Impact Factor=3.2; Impact Factor 2024=4.5; Typ=Journal Article;

Zschäbitz S, Biernath N, Hilser T, Höllein A, Zengerling F, Cascucelli J, Paffenholz P, Seidl D, Lutz C, Schlack K, Kingreen D, Klümper N, Ivanyi P, von Amsberg G, Heers H, Roghmann F, Tauber RL, Cathomas R, Hofer L, **Niegisch G**, Klee M, Ehrenberg R, Hassler A, Hadaschik BA, Grünwald V, Darr C  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 543479

Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates.

**Exp Hematol Oncol** 2023; 12(1): ; Impact Factor=9.4; Impact Factor 2024=13.5; Typ=Letter;

**Wakileh GA, Bierholz P, Kotthoff M, Skowron MA**, Bremmer F, **Stephan A**, Anbuhl SM, Heukers R, Smit MJ, Ströbel P, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 537658

CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners.

**FEBS J** 2023; 290(20): 4864-4876; Impact Factor=5.5; Impact Factor 2024=4.2; Typ=Journal Article;

**Söhngen C, Thomas DJ, Skowron MA**, Bremmer F, Eckstein M, Stefanski A, Driessen MD, **Wakileh GA**, Stühler K, Altevogt P, Theodorescu D, Klapdor R, Schambach A, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 541954

Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells.

**Front Oncol** 2023; 13(): ; Impact Factor=3.5; Impact Factor 2024=3.3; Typ=Journal Article;

Frerichs LM, Frerichs B, Petzsch P, Köhrer K, Windolf J, Bittersohl B, **Hoffmann MJ**, Grotheer V

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 536822

Updating germ cell tumour pathogenesis - the ability of seminomas for FOXA2-driven extra-embryonic differentiation.

**Histopathology** 2023; 83(3): 477-481; Impact Factor=3.9; Impact Factor 2024=4.1; Typ=Journal Article;

Bremmer F, Lubk L, Ströbel P, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 506809

Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial.

**Int J Cancer** 2023; 152(5): 854-864; Impact Factor=5.7; Impact Factor 2024=4.7; Typ=Journal Article;

Krilaviciute A, **Albers P, Lakes J, Radtke JP**, Herkommer K, Gschwend J, Peters I, Kuczyk M, Koerber SA, Debus J, Kristiansen G, Schimmöller L, Antoch G, Makowski M, Wacker F, Schlemmer H, Benner A, Giesel F, Siener R, **Arsov C**, Hadaschik B, Becker N, Kaaks R

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 508156

Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic.

**J Cancer Res Clin Oncol** 2023; 149(2): 913-919; Impact Factor=2.7; Impact Factor 2024=2.8;

Typ=Letter;

Arndt V, Doege D, Fröhling S, **Albers P**, Algül H, Bargou R, Bokemeyer C, Bornhäuser M, Brandts CH, Brossart P, Brucker SY, Brümmendorf TH, Döhner H, Gattermann N, Hallek M, Heinemann V, Keilholz U, Kindler T, von Levezow C, Lordick F, Neumann UP, Peters C, Schadendorf D, Stilgenbauer S, Zander T, Zips D, Braun D, Seufferlein T, Nettekoven G, Baumann M  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 536540

Cumulative sum analysis (CUSUM) for evaluating learning curve (LC) of robotic-assisted laparoscopic partial nephrectomy (RALPN).

**J Robot Surg** 2023; 17(5): 2089-2098; Impact Factor=2.2; Impact Factor 2024=3.0; Typ=Journal Article; Al-Nader M, **Radtke JP**, Püllen L, Darr C, Kesch C, Hess J, Krafft U, Hadaschik BA, Harke N, Mahmoud O

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 535974

Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.

**Lancet Oncol** 2023; 24(4): 347-359; Impact Factor=41.6; Impact Factor 2024=35.9; Typ=Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't;

Grimm MO, Grün CB, **Niegisch G**, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 562792

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.

**Lancet Oncol** 2023; 24(11): 1252-1265; Impact Factor=41.6; Impact Factor 2024=35.9; Typ=Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't;

Grimm MO, Esteban E, Barthélémy P, Schmidinger M, Busch J, Valderrama BP, Charnley N, Schmitz M, Schumacher U, Leucht K, Foller S, Baretton G, Duran I, de Velasco G, Priou F, Maroto P, Albiges L, TITAN-RCC study group

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 534948

Improved diffusion-weighted imaging of the prostate: Comparison of readout-segmented and zoomed single-shot imaging

**Magn Reson Imaging** 2023; 98(): 55-61; Impact Factor=2.1; Impact Factor 2024=2.0; Typ=

Klingebiel M, Weiland E, Boschheidgen M, Ullrich T, **Arsov C**, **Radtke JP**, Benkert T, Nickel M, Strecker R, Wittsack HJ, **Albers P**, Antoch G, Schimmoeller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 509043

PSMA-1007 Uptake in Ganglia of the Sympathetic Trunk and Its Intra-individual Reproducibility.

**Mol Imaging Biol** 2023; 25(3): 554-559; Impact Factor=3.0; Impact Factor 2024=2.5; Typ=Journal Article;

Mamlins E, Schmitt D, Beu M, Mattes-György K, Henke JM, Antke C, Novruzov E, Cardinale J, Kirchner J, **Niegisch G**, **Radtke JP**, Schimmöller L, **Albers P**, Antoch G, Giesel FL

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 534739

Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options

**Mol Med** 2023; 29(1): ; Impact Factor=6.0; Impact Factor 2024=6.4; Typ=

**Skowron MA**, **Kotthoff M**, Bremmer F, **Ruhnke K**, **Parmaksiz F**, Richter A, Kueffer S, Reuter-Jessen K, Pauls S, Stefanski A, Stroebel P, Stuehler K, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 529486

Rucaparib or Physician's Choice in Metastatic Prostate Cancer.

**N Engl J Med** 2023; 388(8): 719-732; Impact Factor=96.2; Impact Factor 2024=78.5; Typ=Randomized Controlled Trial;Clinical Trial, Phase III;Journal Article;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't;

Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH, TRITON3 Investigators

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 538856

The German Network for Personalized Medicine to enhance patient care and translational research.

**Nat Med** 2023; 29(6): 1298-1301; Impact Factor=58.7; Impact Factor 2024=50.0; Typ=Letter;

Illert AL, Stenzinger A, Bitzer M, Horak P, Gaidzik VI, Möller Y, Beha J, Öner Ö, Schmitt F, Laßmann S, Ossowski S, Schaaf CP, Hallek M, Brümmendorf TH, **Albers P**, Fehm T, Brossart P, Glimm H, Schadendorf D, Bleckmann A, Brandts CH, Esposito I, Mack E, Peters C, Bokemeyer C, Fröhling S, Kindler T, Algül H, Heinemann V, Döhner H, Bargou R, Ellenrieder V, Hillemanns P, Lordick F, Hochhaus A, Beckmann MW, Pukrop T, Trepel M, Sundmacher L, Wesselmann S, Nettekoven G, Kohlhuber F, Heinze O, Budczies J, Werner M, Nikolaou K, Beer AJ, Tabatabai G, Weichert W, Keilholz U, Boerries M, Kohlbacher O, Duyster J, Thimme R, Seufferlein T, Schirmacher P, Malek NP

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 534756

Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC).

**Pharmacoecon Open** 2023; 7(3): 469-477; Impact Factor=2.0; Impact Factor 2024=2.1; Typ=Journal Article;

Cooper OAE, Ghatnekar O, Piglowska N, Smith CA, Swinburn P, Catto JWF, **Niegisch G**, Jakobsen JS

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 534775

[Patient management difficulties in case of supposed negative prostate mpMRI].

**Rofo** 2023; 195(7): 616-619; Impact Factor=1.3; Impact Factor 2024=1.7; Typ=Journal Article;

Drewes L, Boschheidgen M, Sommer B, **Radtke JP**, Lopez-Cotarelo C, Giesel FL, Antoch G, Schimmoeller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 543488

Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study.

**Sci Rep** 2023; 13(1): ; Impact Factor=3.8; Impact Factor 2024=3.9; Typ=Multicenter Study;Journal Article;Research Support, Non-U.S. Gov't;

Váradi M, Horváth O, Módos O, Fazekas T, **Grunewald CM**, **Niegisch G**, Krafft U, Grünwald V,

Hadaschik B, Olah C, Maráz A, Furka A, Szúcs M, Nyirády P, Szarvas T  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 540056

Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial.

**Urol Oncol** 2023; 41(8): 356.e19-356.e30; Impact Factor=2.4; Impact Factor 2024=2.3;

Typ=Randomized Controlled Trial;Clinical Trial, Phase III;Journal Article;Research Support, Non-U.S. Gov't;

Heinzelbecker J, Spieler N, Kuehn M, Fischer C, Volkmer B, von Rundstedt F, **Albers P**, Becht E, Bannowsky A, Weber HM, Hofmann R, Müller M, Langbein S, Steiner G, Retz M, Kamradt J, Wagenpfeil G, Wellek S, Lehmann J, Stoeckle M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 548099

BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.

**Urol Oncol** 2023; 41(12): 484.e17-484.e26; Impact Factor=2.4; Impact Factor 2024=2.3;

Typ=Multicenter Study;Journal Article;

Ecke TH, Meisl CJ, Schlomm T, Rabien A, Labonté F, Rong D, Hofbauer S, Friedersdorff F, Sommerfeldt L, Gagel N, Gössl A, Barski D, Otto T, **Grunewald CM**, **Niegisch G**, Hennig MJP, Kramer MW, Koch S, Roggisch J, Hallmann S, Weiß S, Waldner M, Graff J, Veltrup E, Linden F, Hake R, Eidt S, Wirtz RM

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 536463

Gothenburg-2 study - PSA (prostate-specific antigen)-based prostate cancer screening with an early start before the age of 55

**Urologie** 2023; 62(7): 727-729; Impact Factor=0.5; Impact Factor 2024=0.4; Typ=

**Wolframm B**, **Huebner A**, Handke AE, **Bushoff I**, **Lakes J**, **Al-Monajjed R**, **Albers P**, **Radtke JP**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 548074

[Prostate cancer-multiparametric MRI and alternative approaches in intervention and therapy planning].

**Urologie** 2023; 62(11): 1160-1168; Impact Factor=0.5; Impact Factor 2024=0.4; Typ=Systematic

Review;English Abstract;Journal Article;Review;

Handke AE, Ritter M, **Albers P**, Noldus J, **Radtke JP**, Krausewitz P

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 536473

[Research in bladder cancer: translation into the clinic-report of 13th annual meeting of the German Research Group on Bladder Cancer (DFBK) in Berlin].

**Urologie** 2023; 62(6): 636-639; Impact Factor=0.5; Impact Factor 2024=0.4; Typ=Journal Article;

Ecke TH, Wirtz RM, Friedersdorff F, Füssel S, **Hoffmann MJ**, Gaisa NT, Nawroth R

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 536829

[Sequential therapy of advanced bladder cancer after prior perioperative systemic treatment :

Recommendations from the Interdisciplinary Bladder Carcinoma Working Group (IABC) of the DKG e. V.].

**Urologie** 2023; 62(10): 1064-1069; Impact Factor=0.5; Impact Factor 2024=0.4; Typ=English

Abstract;Journal Article;Review;

Retz M, Kirchhoff FP, von Amsberg G, De Santis M, Krege S, Gschwend JE, **Niegisch G**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 538831

[Systematic or targeted fusion-guided biopsy].

**Urologie** 2023; 62(5): 464-472; Impact Factor=0.5; Impact Factor 2024=0.4; Typ=English

Abstract;Journal Article;Review;

Handke AE, **Albers P**, Schimmöller L, Bonekamp D, Asbach P, Schlemmer HP, Hadaschik BA, **Radtke JP**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 507608

[The KomMent study: a pilot project on structured interprofessional communication in uro-oncology].

**Urologie** 2023; 62(3): 271-278; Impact Factor=0.5; Impact Factor 2024=0.4; Typ=English

Abstract;Journal Article;

Jünger J, Fugmann D, Hinding B, Necknig U, Bushuven S, Zschäbitz S, **Steiner N**, **Albers P**, **Giessing M**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

